Skip Navigation

Cardiovascular Research 1995 30(6):866-874; doi:10.1016/S0008-6363(95)00122-0
© 1995 by European Society of Cardiology
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chen, L.Y.
Right arrow Articles by Mehta, J.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, L.Y.
Right arrow Articles by Mehta, J.L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1995, European Society of Cardiology

Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis

L.Y. Chena, W.W. Nicholsa, C. Mattssonb, A-C. Teger-Nilsonb, R. Wallinc, T.G.P. Saldeenc and J.L. Mehta*

aDepartments of Medicine, University of Florida College of Medicine and the VA Medical Center, Gainesville, FL, USA
bPreclinical Research and Development, Astra-Hãssle AB, Mölndal, Sweden
cUniversity of Uppsala, Uppsala, Sweden

* Corresponding author. Box 100277, JHMHC, University of Florida, Gainesville, FL 32610, USA. Tel. (+1-904) 376-1611 ext. 6843; Fax (+1-904) 374-6113.

Objectives: Coronary artery often reoccludes after thrombolytic therapy with recombinant tissue-plasminogen activator (rt-PA). This reocclusion is thought to be due to in situ platelet activation mediated by thromboxane (Tx) A2 and thrombin; hence, aspirin and thrombin inhibitors are often used in patients with acute myocardial infarction. This study was designed to examine the modulation of coronary artery reocclusion by a novel low molecular weight direct thrombin inhibitor inogatran with or without aspirin. Methods: 22 dogs with electrically-induced occlusive intracoronary thrombus were treated with saline (n = 7, group A), or high dose inogatran (0.25 mg/kg bolus followed by 0.6 mg/kg per h for 2 h, n = 5, group B), or low dose inogatran (0.125 mg/kg bolus followed by 0.3 mg/kg per h for 2 h, n = 5, group C), or aspirin + low dose inogatran (n = 5, Group D). Recombinant tissue-plasminogen activator (rt-PA) was infused for 20 min starting 2 min after the bolus in all dogs. Coronary artery blood flow was monitored for 120 min after rt-PA administration. Results: Reperfusion rates were similar in all groups, but the time to reperfusion was shortest in group B dogs (18 ± 2 min vs. 32 ± 7 min in group A dogs, P < 0.05). Reocclusion rates were 80%, 0%, 50%, and 60% in groups A, B, C, and D dogs, respectively. The restored blood flow persisted for 19 ± 10, ± 120 min, 71 ± 30 and 54 ± 26 min in groups A, B, C, and D dogs, respectively. At the end of rt-PA infusion, prothrombin time (PT) and activated partial thromboplastin time (APTT) were increased 1.3–2 times the control value, and the changes in PT and APTT were similar in all groups. Thrombin generation and activity, assessed by rise in thrombin-antithrombin complex and fibrinopeptide A levels, and decrease in fibrinogen levels were most marked in group A dogs, and less so in group B, C and D dogs. Conclusions: These data show that high dose of direct thrombin inhibitor inogatran shortens time to reflow and abolishes coronary artery reocclusion. However, aspirin does not potentiate the effect of suboptimal doses of inogatran.

KEYWORDS Aspirin; t-PA; Thrombin inhibitors; Thrombolysis; Dog; anesthetized


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
L. S. Wilson, H. S. Elbatarny, S. W. Crawley, B. M. Bennett, and D. H. Maurice
Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions
PNAS, September 9, 2008; 105(36): 13650 - 13655.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. D. Lewis, C. Witzke, P. Colon-Hernandez, J. L. Guerrero, K. D. Bloch, and M. J. Semigran
Sildenafil Improves Coronary Artery Patency in a Canine Model of Platelet-Mediated Cyclic Coronary Occlusion After Thrombolysis
J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1471 - 1477.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.